OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Headache and Pain is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis	480
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description	239
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition	150
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II	109
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study	105
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine	87
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency	84
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	74
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	68
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study	63
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache	59
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States	58
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan	57
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation	56
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials	56
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study	55
Characteristics of N400 component elicited in patients who have migraine with aura	49
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks	49
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke	49
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients	48
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine	47
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China	47
Age- and frequency-dependent changes in dynamic contrast perception in visual snow syndrome	45
Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary	43
Debate: Are cluster headache and migraine distinct headache disorders?	42

CGRP and PACAP-38 play an important role in diagnosing pediatric migraine	40
Measuring interictal burden among people affected by migraine: a descriptive survey study	40
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey	39
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia	39
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	39
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI	36
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results	35
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial	35
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury	35
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study	33
A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN	33
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States	33
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting	32
Attenuated alpha oscillation and hyperresponsiveness reveals impaired perceptual learning in migraineurs	32
Correction to: Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic revi	32
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study	31
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany	31
Inflammatory complications of CGRP monoclonal antibodies: a case series	30
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials	30
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension	29
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phas	28
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study	28
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study	28
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model	27
Altered effective connectivity in migraine patients during emotional stimuli: a multi-frequency magnetoencephalography study	27
Development and validation of a novel model for characterizing migraine outcomes within real-world data	27
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain	27
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-ana	26
Tracking the evolution of non-headache symptoms through the migraine attack	26
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients	26
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy	26
Osmophobia in primary headache patients: associated symptoms and response to preventive treatments	26
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism	26
Age-related differences in resting state functional connectivity in pediatric migraine	25
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study	25
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies	25
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report	24
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study	24
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials	24
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients	24
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study	24
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials	24
Correction: Burden of tension-type headache in the Middle East and North Africa region, 1990-2019	23
Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study	23
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients	23
Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank	23
Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review	23
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience	23
Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology	23
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)	23